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Objectives
• Why are we where we are?
• What evidence exists in what spaces?
• What we think happens vs what our patients are actually doing

Background
• 1930 : Bureau of Narcotics formed
• 1932 :  Uniform State Narcotic Drug Act- safe regulation in all states.
• Marijuana Tax Act of 1937 
• 1952 – 1956 :  Set mandatory penalties for cannabis offenses
Background
• 1970
• Controlled Substances Act in the 1970’s 
• Schedules for ranking substances according to their dangerousness and potential for addiction
• 1 = drugs with no currently accepted medical use and a high potential for abuse
• LSD, 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone(Quaalude), and peyote
• 2 = opioids, cocaine, stimulants (Ritalin, Adderall) 
• Marijuana classified as Schedule 1
• 1973-1978 
• 11 states decriminalized cannabis
• 1996
• California  - The compassionate Use Act  First state to permit use of cannabis prescribed 
by a physician
• 2012
• Colorado legalized recreational use of cannabis
Where Do We Stand Today?
http://www.governing.com/gov-data/state-
marijuana-laws-map-medical-recreational.html
•Thirty states and the District of 
Columbia currently have laws legalizing 
marijuana in some form
•Eight states and the District of 
Columbia have adopted laws legalizing 
marijuana for recreational use
•A number of states have also 





The Legal Issue is Complicated: Federal vs State Laws
• Can federal government punish physicians who recommend medical 
marijuana?
• Conant v. Walters. The U.S. Court of Appeals for the Ninth Circuit ruled that doctors 
cannot be punished, or even investigated, solely for recommending medical marijuana, 
because doing so is protected free speech. The U.S. Supreme Court let the decision 
stand
• Can doctors be prosecuted for signing a certification?
• Pennsylvania’s law indicates that a physician is not subject to arrest, prosecution, or 
penalty in any manner, or denied any right or privilege including civil penalty or 
disciplinary action, solely for his or her participation in the program. Sec. 2103 (A)(3)
Legal Questions
• State  
• Online only access to registry (what form of ID required)?
• Dispensaries allowed?
• Specific conditions?
• Recognize patients from other states?
• Condition specific vs purchases 
• Federal
• Occupation
• Gun License 
https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx
Should cannabis be considered a medication?
• Recently reinstated into US Pharmacopeia 
• THC predominant, CBD Predominant, Intermediate 
• Herbal supplement?  FDA approved medication?
• Differences between dronabinol (Marinol), cannabidiol (Epidiolex) and cannabis 
• Likely never possible to distill out and replicate specific phytochemicals 

What evidence is there? . . . .
• There is a large methodological problem in ALL cannabis related research 
• Placebo vs active control
• Randomization, blinding 
• Washout period
• Synthetic vs natural, single phytochemical vs ‘broad spectrum’ 
• Route of administration 
• Inhalation (most commonly used, least commonly studied), oral, rectal, topical, transdermal, 
ocular, intravenous 
• Dosing 
Evaluating the Literature 
• Risk of AE’s
• Determine if definition of adverse event is clinically meaningful
• Sedation vs dizziness vs short term memory impairment vs tachycardia vs dry mouth vs 
psychosis 
Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people 
with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and 
observational studies. Pain. 2018;159:1932-54.
“In chronic noncancer pain, cannabinoids reduce pain (NNT 24) but 
increase adverse events (NNH 6)”
Epilepsy 
• Lennox-Gastaut Syndroms (LGS) and Dravat
Syndrome
• Open-Label Study of Epidiolex (99% CBD), 12 
weeks,  published in Lancet Neurology in 2016
• 214 patients 
• People who received Epidiolex ranged from 
2 to 26 years old with an average age of 11.
• All had epilepsy that did not respond to 
currently available treatments.
• During the study, seizures decreased by an 
average of 54%.
Pain 
• Cancer pain 
• Non cancer pain 
• Inc spasticity  
• NP pain 
• Post op pain
Aviram J, Samuelly-Leichtag G. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic 
Review and Meta-Analysis of Randomized Controlled Trials. Pain Physician. 2017 Sep;20(6):E755-E796. PMID: 
28934780.
Nausea & Vomiting
• Known cannabinoid receptors within the brain stem and 
higher brain centers involved in N/V
• Systematic Review of 30 trials - 2001
• Nabilone, dronabinol, IM levonantradol – only synthetics
• More effective in relieving N/V with chemotherapy than 
many other anti-emetics.  
• NNT = 8
• SE = dizziness, dysphoria, sedation 
• Dronabinol – FDA approved in 1986 for N/V
BMJ 2001;323:1–8






• AIDS “wasting syndrome”
• Before HAART in early 1990’s
• cannabis buyers’ clubs in the San Francisco Bay area were reportedly selling marijuana 
to 11,000 patients with HIV infection
• Marinol expanded FDA approval in 90’s for this
• Cancer cachexia 
• Some evidence of increased appetite with either no or some improvement in body 
weight
• But. . . . Only looking at marinol/nabilone and very sparse trials 
Suzuki, Hajime, et al. "Cancer cachexia—pathophysiology and management." Journal of gastroenterology 48.5 (2013): 574-594.











• 21st century, most widely used illegal drug in the world
• UN estimating up to 192 million people consumed cannabis in 2018
• Most users experience “mild euphoria, relaxation, perceptual alterations including 
time distortion and intensification of ordinary experiences such as eating, 
watching films, listening to music and engaging in sex” 
Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374(9698):1383-
1391
Does cannabis use increase the risk of psychiatric disorders?
Blanco C, Hasin DS, Wall MM, et al. Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National 
Longitudinal Study. JAMA Psychiatry. 2016;73(4):388–395. doi:10.1001/jamapsychiatry.2015.3229
Abuse and psychiatric illness 
• Heavy use 6.2x the risk of hospitalization for psychosis 
• Swedish study followed 50,000 people for 27 yrs
• >50 uses = 7x more likely to have schizophrenia than never users
• Chicken or the egg??
• Does it really “cause” schizophrenia vs heavy use more likely in individuals with 
schizophrenia/genetic predisposition to schizophrenia
• Australian study
• 10 fold increase in marijuana use 
• No change in rates of schizophrenia over last 40 yrs




• Chronic cannabis use, cyclical nausea and vomiting episodes
• 3 phases
• Prodromal
• Increased cannabis use believing it is helpful 
• Hyperemetic
• Recovery
• Treatment – supportive, cessation of cannabis
• Often confused with cyclical vomiting syndrome 
Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid Hyperemesis Syndrome. Current 
drug abuse reviews. 2011;4(4):241-249.
Addiction
• Prevalence of use peaks in late teens – 20’s






• Risk of dependence after 25 yr is essentially zero
• Withdrawal syndrome  
Robson P. Abuse potential and psychoactive effects of -9 tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011;10(5):675
What We Don’t Know 
• Shi, Yuyan. "Medical marijuana policies and hospitalizations related to marijuana 
and opioid pain reliever." Drug and alcohol dependence 173 (2017): 144-150.
• Hospitalizations related to marijuana and opioid have risen by 300%
• Medical marijuana legalization reduced opioid-related hospitalizations.
• Medical marijuana legalization had no impacts on marijuana-related hospitalizations
What we think happens. . . . What really happens . . . 
Cannabis Derived Formulations in US
• Cannabis “buds” (dried cannabis flowers)
• Cannabis resin (hashish, bubble hash, kief)
• Cannabis concentrates (butane, honey oil, shatter, wax, crumble) 
Wide variations in percent of THC and CBD
Delivery modes:
• Smoking or inhaling cigarettes (joints), pipes (bowls), water pipes (bongs, 
hookahs), blunts (cigars filled with cannabis)
• Edibles – food products
• Vaporizing




• >10,000 active registrants, >500 ‘family representatives’
• Find a registered physician to ‘certify’
• 2% of physicians in NJ (1% in NY)
• Apply through state and pay fee - $250
• Dispensary “Alternative Treatment Center”
https://www.pa.gov/guides/pennsylvania-medical-marijuana-program/
Under Pennsylvania medical marijuana law, “medical marijuana may 
only be dispensed to a patient or caregiver in the following forms”:
• Pill
• Oil
• Topical forms, including gel, creams or ointments





• Current PA unrestricted license, DEA, good standing
• Register via DOH
• Complete 4 hour approved course
• Certify patients 
• Complete form, submit to DOH
• Medical record must include dx of a qualifying condition
• Follow up ‘at least annually’
• Patients
• Sign up with DOH
• See certified physician (fee)
• Pay registration fee $50 for card
• Visit dispensary
How to help guide patients
• Do you have a reason to medically prefer a specific form?
• Inhale vs oral vs topical 
• Focus on THC and CBD alone – we don’t know enough about anything else
• Talk in broad strokes - THC predominant, CBD Predominant, Intermediate 
• How experienced is the patient? Start where they are
• Follow up and document!
